Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Time

<< Previous

Bullboard Posts

Next >>

Comment by PlaySafeon Aug 12, 2021 2:59pm

138 Views

Post# 33695256

RE:RE:RE:RE:RE:Time

If what you say is true and Antibe knew and had all of this information then why did they not power the 150mg dose for statistical significance during Phase 2B. Furthermore, I hear the words "unexpected results" as part of the AME PR. So do you really think that they fully undestand what their drug is doing? Furthermore, have you ever heard of the term "placebo-effect" for drug trials and that being one of the main reasons drug trials fail Phase 2. So here we are re-doing Phase 2 all over again....if that isn't additional risk then I don't know what is.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading